In conclusion, our study revealed that PARP10 was aberrantly expressed in AML patients, and its high expression was associated with high-risk factors and poor prognosis and could be an independent poor survival factor in AML patients. The gene discussed is PARP10; the disease is acute myeloid leukemia.